Page 71 - 2020_11-Haematologica-web

Translational and clinical advances in aGvHD
prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone mar- row (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733-741.
54. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.
55. Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft versus host disease and relapse associated with T-cell depleted peripheral blood stem cell transplantation for acute myeloid leukemia in first remis- sion: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. Biol Blood Marrow Transplant. 2011;17(9):1343-1351.
56. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophy- laxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoi- etic cell transplantation. J Clin Oncol. 2012;30(26):3194-3201.
57. Daniele N, Scerpa MC, Caniglia M, et al. Transplantation in the onco-hematology field: focus on the manipulation of aβ and γd T cells. Pathol Res Pract. 2012;208(2):67-73.
58. Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after aβ T- cell and B-cell depletion. Blood. 2017;130(5):677-685.
59.Distler E, Bloetz A, Albrecht J, et al. Alloreactive and leukemia-reactive T cells are preferentially derived from naïve precur- sors in healthy donors: implications for immunotherapy with memory T cells. Haematologica. 2011;96(7):1024-1032.
60.Teschner D, Distler E, Wehler D, et al. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant. 2014;49(1):138-144.
61. Bleakley M, Heimfeld S, Jones LA, et al. Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20(5):705-716.
62. Bleakley M, Heimfeld S, Loeb KR, et al. Outcomes of acute leukemia patients trans- planted with naive T cell-depleted stem cell grafts. J Clin Invest. 2015;125(7):2677-2689.
63. Poon LM, Linn YC, Tan PL, et al. HLA-hap- loidentical hematopoietic cell transplanta- tion after TCR-Aβ and CD45RA+ depletion following reduced intensity conditioning in adults and children with hematological malignancies - two-year follow-up of multi- center study in Singapore. Blood. 2019;134(Suppl 1):abstract 2039.
64.Ng CT, Ampudia J, Soiffer RJ, Ritz J, Connelly S. Itolizumab as a potential thera- peutic for the prevention and treatment of graft vs host disease. Blood. 2019;134(Suppl 1):5603.
65. Aversa F, Pierini A, Ruggeri L, Martelli MF, Velardi A. The evolution of T cell depleted haploidentical transplantation. Front Immunol. 2019;10:2769.
66. Rachamim N, Gan J, Segall H, et al. Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent spe- cific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lympho- cyte culture. Transplantation. 1998;65(10):
1386-1393.
67. Di Ianni M, Falzetti F, Carotti A, et al. Tregs
prevent GVHD and promote immune reconstitution in HLA-haploidentical trans- plantation. Blood. 2011;117(14):3921-3928.
68. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
69. Parmar S, Liu X, Najjar A, et al. Ex vivo fuco- sylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo. Blood. 2015;125(9):1502- 1506.
70. Copsel SN, Barreras H, Lightbourn CO, et al. IL-2/IL-2R, TL1A/TNFRSF25 or their com- bined stimulation results in distinct CD4+FoxP3+ regulatory T cell phenotype and suppressive function. Biol Blood Marrow Transplant. 2020;26(3):S169.
71.Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-1070.
72. Mavers M, Maas-Bauer K, Negrin RS. Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2017;8:900.
73. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus- host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol. 2007;178(10):6242-6251.
74. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4- dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458-4467.
75.Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-ver- sus-host disease. N Engl J Med. 2005;353(13):1321-1331.
76.Duramad O, Laysang A, Li J, Nguyen N, Ishii Y, Namikawa R. A liposomal formula- tion of KRN7000 (RGI-2001) potently reduces GvHD lethality through the expan- sion of CD4+Foxp3+ regulatory T cells in murine models. Blood. 2008;112(11):3500.
77.Chen Y-B, Efebera YA, Johnston L, et al. Increased Foxp3+Helios+ regulatory T cells and decreased acute graft-versus-host dis- ease after allogeneic bone marrow trans- plantation in patients receiving sirolimus and RGI-2001, an activator of invariant nat- ural killer T cells. Biol Blood Marrow Transplant. 2017;23(4):625-634.
78. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2011;17(1):77-88.
79.Drobyski WR, Szabo A, Zhu F, et al. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastroin- testinal tract disease. Haematologica. 2018;103(4):717-727.
80. Kennedy GA, Tey S-K, Curley C, et al. Results of a phase III double-blind study of the addition of tocilizumab vs. placebo to cyclosporin/methotrexate GvHD prophy- laxis after HLA-matched allogeneic stem cell transplantation. Blood. 2019;134(Suppl 1):368.
81. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal
82.
83.
murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83(12): 3815-3825. Watkins B, Qayed M, Bratrude B, et al. T cell costimulation blockade with abatacept near- ly eliminates early severe acute graft versus host disease after HLA-mismatched (7/8 HLA matched) unrelated donor transplant, with a favorable impact on disease-free and overall survival. Blood. 2017;130(Suppl 1):212.
Watkins BK, Tkachev V, Furlan SN, et al. CD28 blockade controls T cell activation to prevent graft-versus-host disease in pri- mates. J Clin Invest. 2018;128(9):3991-4007.
84. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7):387- 394.
85. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methyl- prednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92(7):2288- 2293.
86. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, von Bubnoff N. Ruxolitinib for the treatment of patients with steroid- refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018;10(5):391-402.
87. Choi J, Ziga ED, Ritchey J, et al. IFNγR sig- naling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120(19):4093-4103.
88. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123 (24):3832-3842.
89.Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft- versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.
90.Jagasia M, Ali H, Schroeder MA, et al. Ruxolitinib in combination with corticos- teroids for the treatment of steroid-refracto- ry acute graft-vs-host disease: results from the phase 2 REACH1 trial. Biol Blood Marrow Transplant. 2019;25(3):S52.
91.Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810.
92. Tawara I, Sun Y, Lewis EC, et al. Alpha-1- antitrypsin monotherapy reduces graft-ver- sus-host disease after experimental allogene- ic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564-569.
93. Marcondes AM, Hockenbery D, Lesnikova M, et al. Response of steroid-refractory acute GVHD to a1-antitrypsin. Biol Blood Marrow Transplant. 2016;22(9):1596-1601.
94. Magenau JM, Goldstein SC, Peltier D, et al. a1-antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host dis- ease. Blood. 2018;131(12):1372-1379.
95. Fløisand Y, Lazarevic VL, Maertens J, et al. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastroin- testinal acute graft-versus-host disease: a ret- rospective record review. Biol Blood Marrow Transplant. 2019;25(4):720-727.
96. Kekre N, Kim HT, Ho VT, et al. Phase II trial of natalizumab (Tysabri®) with corticos- teroids as initial treatment of gastrointestinal acute graft versus host disease. Biol Blood Marrow Transplant. 2018;24(3):S81.
97. Klassen J. The role of photopheresis in the
haematologica | 2020; 105(11)
2559